Abstracts tagged "Vasculitis"

Abstract Number: 1550 • ACR Convergence 2022
Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
SEMA KAYMAZ-TAHRA¹, Salih Ozguven², Nuh Filizoglu², Ali Ugur Unal³, Fatma Alibaz-Oner⁴, Tunc Ones², Tanju Yusuf Erdil² and Haner Direskeneli⁵, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Rheumatology, Istanbul, Turkey, ²Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, ³Marmara University School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: Iliofemoral artery disease, which is commonly observed in severe atherosclerosis, may also be present in Takayasu's arteritis (TAK). In this study we aimed to…
Abstract Number: 1574 • ACR Convergence 2022
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Alicia Rodriguez-Pla, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…
Abstract Number: 2230 • ACR Convergence 2022
Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study
Yiming Luo¹, Marcela Ferrada¹, Keith Sikora², Daniel Kastner³, Zuoming Deng⁴, Mengqi Zhang⁵, Hugh Alessi¹, Virginia Kraus⁶, Andrew Allen⁶ and Peter Grayson⁷, ¹National Institutes of Health, Bethesda, MD, ²National Institutes of Health Clinical Center, Bethesda, MD, ³National Human Genome Research Institute, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Duke University, Durham, NC, ⁷National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare rheumatic disease of unknown etiology characterized by inflammations of cartilaginous structures and other tissues, particularly the ears, nose,…
Abstract Number: 0462 • ACR Convergence 2022
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
Mohanad Elfishawi¹, Mahmut Kaymakci², Sara Achenbach³, Cynthia Crowson⁴, Tanaz Kermani⁵, Cornelia Weyand⁴, Matthew J. Koster¹ and Kenneth J. Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Mayo Clinic, Eyota, MN, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Screening for large artery manifestations has been adopted by clinicians managing patients with Giant Cell Arteritis (GCA). The contemporary effect of the increased use…
Abstract Number: 0487 • ACR Convergence 2022
A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis
Catalina Sanchez Alvarez¹, Milena Bond², Medha Soowamber³, Dario Camellino⁴, Zahi Touma⁵, Sofia Ramiro⁶, Melanie Anderson⁷, Carol Langford⁸ and Christian Dejaco⁹, ¹University of Florida, Gainesville, FL, ²Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Mount Sinai Hospital, Woodbridge, ON, Canada, ⁴Azienda Sanitaria Locale 3 Genoa, Genoa, Italy, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷University Health Network, Toronto, ON, Canada, ⁸Cleveland Clinic, Cleveland, OH, ⁹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. While remission and relapse are common primary endpoints in clinical trials,…
Abstract Number: 1075 • ACR Convergence 2022
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Jane Bentley⁴, Jonathan Steinfeld⁵, Steven Yancey⁶, Namhee Kwon⁷, Praveen Akuthota⁸, Paneez Khoury⁹, Lee Baylis¹⁰ and Michael Wechsler¹¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, ⁶Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, ⁷Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, ⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, ⁹Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Global Medical Affairs, GlaxoSmithKline, Durham, NC, ¹¹Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
Abstract Number: 1551 • ACR Convergence 2022
The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis
Saja Almaaitah¹, Chao Zhang² and alexandra villa forte¹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Takayasu Arteritis (TA) is a complex large vessel vasculitis that leads to arterial stenosis, occlusion and aneurysmal formation. Assessment of disease activity is a…
Abstract Number: 1575 • ACR Convergence 2022
Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Larson⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of California Los Angeles, Los Angeles, CA, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵University of South Florida, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
Abstract Number: 2232 • ACR Convergence 2022
Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients
Julien ROHMER¹, ludovic trefond², Yann Nguyen³, Christian Agard⁴, Jean Sebastien ALLAIN⁵, Alice Berezne⁶, Pierre Charles⁷, Pascal Cohen⁸, guillaume gondran⁹, Matthieu GROH¹⁰, Tessa HUSCENOT¹¹, carole lacout¹², Estibaliz Lazaro¹³, Jonathan London¹⁴, Francois Maurier¹⁵, Arsene Mekinian¹⁶, Isabelle Nubourgh¹⁷, Rafik MESBAH¹⁸, Xavier Puéchal⁸, Laurent Perard¹⁹, Mathieu Puyade²⁰, Gregory Pugnet²¹, Viviane Queyrel²², Diane Rouzaud²³, Arthur Roux²⁴, Cecile-Audrey DUREL¹⁹, Loïc Guillevin⁸ and Benjamin Terrier⁸, ¹APHP, Suresnes, France, ²Chu clermont ferrand, Clermont-Ferrand, France, ³AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵CHU rennes, Rennes, ⁶CH Annecy, Annecy, France, ⁷Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁹CHU limoges, Limoges, France, ¹⁰Foch Hospital, Suresnes, France, ¹¹APHP, Boulogne, France, ¹²CHU Angers, Angers, France, ¹³Bordeaux Hospital University, Bordeaux, France, ¹⁴Hôpital Croix-Saint-Simon, Paris, France, ¹⁵Hôpitaux privés de Metz, Metz, France, ¹⁶AP-HP, Hopital Saint Antoine, Paris, France, ¹⁷Ch St Pierre, Brussels, Belgium, ¹⁸Boulogne Ch, Boulogne, France, ¹⁹CHU Lyon, Lyon, France, ²⁰Centre Hospitalier Universitaire de Poitiers, Poitiers, France, ²¹CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, ²²CHU NIce, Nice, France, ²³Bichat, Paris, France, ²⁴MGEN, Paris, France
Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
Abstract Number: 0038 • ACR Convergence 2022
STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)
Sachin Gaurav¹, Bin Lin², Sophia Park³, Shankar Venkatraman⁴, David Winkler⁴ and Raphaela Goldbach-Mansky⁵, ¹Translational Autoinflammatory Diseases Section, LCIM, NIAID,, Bethesda, MD, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴IFM Therapeutics, Boston, MA, ⁵NIH/NIAID, Potomac, MD
Background/Purpose: SAVI is a rare, autoinflammatory type I interferonopathy caused by gain-of-function mutations that cause STING activation and excessive production of type I interferons and…
Abstract Number: 0463 • ACR Convergence 2022
Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
Christina Costeas, Shubhasree Banerjee, Madhura Tamhankar, Naomi Amudala, Peter Merkel and Rennie Rhee, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Giant Cell Arteritis (GCA) Fast-Track program was implemented at our center with the goal of accelerating diagnosis of this rare and rapidly progressive…
Abstract Number: 0488 • ACR Convergence 2022
Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center
Raj Vachhani¹, Peng Li², Mehdi Tavakoli², Lanning Kline² and Angelo Gaffo², ¹University of Alabama at Birmingham, Homewood, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: A prior study evaluated incidence rates of biopsy proven giant cell arteritis (GCA) among black and white patients, concluding that GCA occurs at a…
Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Naomi Patel¹, David Jayne², Peter Merkel³, Pirow Bekker⁴, yuqing zhang⁵, Huibin Yue⁴ and John Stone⁶, ¹Massachusetts General Hospital, Sale Creek, TN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴ChemoCentryx, San Juan Capistrano, CA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
Abstract Number: 1552 • ACR Convergence 2022
Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis
Hugh Alessi¹, Yiming Luo¹, Kaitlin Quinn² and Peter Grayson³, ¹NIH, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: A set of genes has been associated with aortopathies, which are defined as non-inflammatory diseases where the integrity of large arteries is compromised leading…
Abstract Number: 1576 • ACR Convergence 2022
Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis
Umar Ghaffar¹, Hannah Langenfeld², Cynthia Crowson³, Tanaz Kermani⁴, Michelle Burke¹, Boyd Viers¹, Aaron Potretzke¹, Haraldur Bjarnason¹, Kenneth J. Warrington¹ and Matthew J. Koster¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴University of California Los Angeles, West Hills, CA
Background/Purpose: To evaluate the presentation features and outcomes of patients with chronic abdominal periaortitis in a large referral cohort. Methods: Using a proprietary medical text…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].